Formononetin attenuates early diabetic retinal and renal microvascular injury associated with EGR1/VEGF-related endothelial responses.
FMN attenuated early diabetes-associated retinal and renal injury and was linked to EGR1/VEGF-related endothelial responses, which support EGR1 involvement but do not establish it as the sole target or mediator of FMN.